Oruka Therapeutics, Inc. ORKA

Oruka Therapeutics' (ORKA) lead program of long-acting IL-23 in moderate-to-severe psoriasis maintai

Oruka Therapeutics recently reported positive Week 28 data from its EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis, showing deepening clinical responses and a safety profile consistent with the IL-23p19 class. An interesting aspect is that placebo patients who later crossed over to ORKA-001 achieved similar response patterns, underscoring the drug’s potential effect even after delayed initiation. Next, we’ll examine how ORKA-001’s high PASI 100 and PASI 90...

Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names.

Oruka Therapeutics Inc. (NASDAQ:ORKA) on Wednesday reported positive week 28 outcomes from its Phase 2a clinical trial evaluating ORKA-001 for moderate-to-severe plaque psoriasis.The clinical-stage biotechnology firm noted that patient responses improved significantly six months after receiving their final dose of the novel antibody.Phase 2a Trial Demonstrates Deepening EfficacyData showed that 63.5% of treated patients achieved complete skin clearance, or PASI 100, at week 16.Clinical improveme

Oruka Therapeutics, Inc. (NASDAQ:ORKA) shares fell 5% on Wednesday morning after the biotechnology company reported Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis.

PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001 ORKA-001 maintained a favorable safety and tolerability profile through Week 28 52-week EVERLAST-A data for all patients expected in December 2026 16-week EVERLAST-B data expected in 4Q 2026 MENLO PARK, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a c

MENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis and hidradenitis suppurativa, today announced its attendance at the 2026 Morgan Stanley Global Healthcare Conference, taking place in New York, NY from September 14-16, 2026.About Oruka TherapeuticsOruka Therapeutics is develop

MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced the appointment of Todd Edwards as Chief Commercial Officer, effective August 24, 2026. Mr. Edwards brings more than 25 years of commercial leadership experience across im